Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
Identifieur interne : 004D33 ( PubMed/Curation ); précédent : 004D32; suivant : 004D34Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
Auteurs : D. Bravi [États-Unis] ; J J Anderson ; F. Dagani ; T L Davis ; R. Ferrari ; M. Gillespie ; T N ChaseSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1992.
English descriptors
- KwdEn :
- Age Factors, Blood Glucose (metabolism), Blood Platelets (drug effects), Blood Platelets (physiology), Carbidopa (administration & dosage), Drug Therapy, Combination, Energy Metabolism (drug effects), Energy Metabolism (physiology), Female, Humans, Lactates (blood), Lactic Acid, Levodopa (administration & dosage), Lisuride (administration & dosage), Male, Middle Aged, Mitochondria (drug effects), Mitochondria (physiology), Oxygen Consumption (drug effects), Oxygen Consumption (physiology), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Receptors, Dopamine (drug effects), Receptors, Dopamine (physiology), Selegiline (administration & dosage).
- MESH :
- chemical , administration & dosage : Carbidopa, Levodopa, Lisuride, Selegiline.
- chemical , blood : Lactates.
- chemical , drug effects : Receptors, Dopamine.
- chemical , metabolism : Blood Glucose.
- drug effects : Blood Platelets, Energy Metabolism, Mitochondria, Oxygen Consumption.
- drug therapy : Parkinson Disease.
- physiology : Blood Platelets, Energy Metabolism, Mitochondria, Oxygen Consumption, Receptors, Dopamine.
- physiopathology : Parkinson Disease.
- Age Factors, Drug Therapy, Combination, Female, Humans, Lactic Acid, Male, Middle Aged.
Abstract
Oxygen consumption and enzyme activity were evaluated in platelet mitochondria from 17 patients with Parkinson's disease. In comparison with age-matched controls, no consistent abnormality could be discerned in complex I, complex II-III, or complex IV oxygen consumption, or in the enzyme activity of these respiratory chain complexes. Neither chronic therapy with levodopa/carbidopa alone nor in combination with deprenyl significantly affected any measure of mitochondrial respiratory function. There was no discernible relationship between patient age or disease severity and any parameter of mitochondrial respiration. Moreover, blood lactate levels following glucose loading were not different in patients and controls. These results fail to support the occurrence of a generalized defect in any mitochondrial respiratory function in Parkinson's disease.
DOI: 10.1002/mds.870070307
PubMed: 1620140
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004D33
Links to Exploration step
pubmed:1620140Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.</title><author><name sortKey="Bravi, D" sort="Bravi, D" uniqKey="Bravi D" first="D" last="Bravi">D. Bravi</name><affiliation wicri:level="2"><nlm:affiliation>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland 20892.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Anderson, J J" sort="Anderson, J J" uniqKey="Anderson J" first="J J" last="Anderson">J J Anderson</name></author><author><name sortKey="Dagani, F" sort="Dagani, F" uniqKey="Dagani F" first="F" last="Dagani">F. Dagani</name></author><author><name sortKey="Davis, T L" sort="Davis, T L" uniqKey="Davis T" first="T L" last="Davis">T L Davis</name></author><author><name sortKey="Ferrari, R" sort="Ferrari, R" uniqKey="Ferrari R" first="R" last="Ferrari">R. Ferrari</name></author><author><name sortKey="Gillespie, M" sort="Gillespie, M" uniqKey="Gillespie M" first="M" last="Gillespie">M. Gillespie</name></author><author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T N" last="Chase">T N Chase</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1992">1992</date><idno type="RBID">pubmed:1620140</idno><idno type="pmid">1620140</idno><idno type="doi">10.1002/mds.870070307</idno><idno type="wicri:Area/PubMed/Corpus">004D33</idno><idno type="wicri:Area/PubMed/Curation">004D33</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.</title><author><name sortKey="Bravi, D" sort="Bravi, D" uniqKey="Bravi D" first="D" last="Bravi">D. Bravi</name><affiliation wicri:level="2"><nlm:affiliation>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland 20892.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Anderson, J J" sort="Anderson, J J" uniqKey="Anderson J" first="J J" last="Anderson">J J Anderson</name></author><author><name sortKey="Dagani, F" sort="Dagani, F" uniqKey="Dagani F" first="F" last="Dagani">F. Dagani</name></author><author><name sortKey="Davis, T L" sort="Davis, T L" uniqKey="Davis T" first="T L" last="Davis">T L Davis</name></author><author><name sortKey="Ferrari, R" sort="Ferrari, R" uniqKey="Ferrari R" first="R" last="Ferrari">R. Ferrari</name></author><author><name sortKey="Gillespie, M" sort="Gillespie, M" uniqKey="Gillespie M" first="M" last="Gillespie">M. Gillespie</name></author><author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T N" last="Chase">T N Chase</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1992" type="published">1992</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term><term>Blood Glucose (metabolism)</term><term>Blood Platelets (drug effects)</term><term>Blood Platelets (physiology)</term><term>Carbidopa (administration & dosage)</term><term>Drug Therapy, Combination</term><term>Energy Metabolism (drug effects)</term><term>Energy Metabolism (physiology)</term><term>Female</term><term>Humans</term><term>Lactates (blood)</term><term>Lactic Acid</term><term>Levodopa (administration & dosage)</term><term>Lisuride (administration & dosage)</term><term>Male</term><term>Middle Aged</term><term>Mitochondria (drug effects)</term><term>Mitochondria (physiology)</term><term>Oxygen Consumption (drug effects)</term><term>Oxygen Consumption (physiology)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Receptors, Dopamine (drug effects)</term><term>Receptors, Dopamine (physiology)</term><term>Selegiline (administration & dosage)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carbidopa</term><term>Levodopa</term><term>Lisuride</term><term>Selegiline</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Lactates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Blood Glucose</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Platelets</term><term>Energy Metabolism</term><term>Mitochondria</term><term>Oxygen Consumption</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Blood Platelets</term><term>Energy Metabolism</term><term>Mitochondria</term><term>Oxygen Consumption</term><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Lactic Acid</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Oxygen consumption and enzyme activity were evaluated in platelet mitochondria from 17 patients with Parkinson's disease. In comparison with age-matched controls, no consistent abnormality could be discerned in complex I, complex II-III, or complex IV oxygen consumption, or in the enzyme activity of these respiratory chain complexes. Neither chronic therapy with levodopa/carbidopa alone nor in combination with deprenyl significantly affected any measure of mitochondrial respiratory function. There was no discernible relationship between patient age or disease severity and any parameter of mitochondrial respiration. Moreover, blood lactate levels following glucose loading were not different in patients and controls. These results fail to support the occurrence of a generalized defect in any mitochondrial respiratory function in Parkinson's disease.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">1620140</PMID><DateCreated><Year>1992</Year><Month>08</Month><Day>04</Day></DateCreated><DateCompleted><Year>1992</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>1992</Year></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>228-31</MedlinePgn></Pagination><Abstract><AbstractText>Oxygen consumption and enzyme activity were evaluated in platelet mitochondria from 17 patients with Parkinson's disease. In comparison with age-matched controls, no consistent abnormality could be discerned in complex I, complex II-III, or complex IV oxygen consumption, or in the enzyme activity of these respiratory chain complexes. Neither chronic therapy with levodopa/carbidopa alone nor in combination with deprenyl significantly affected any measure of mitochondrial respiratory function. There was no discernible relationship between patient age or disease severity and any parameter of mitochondrial respiration. Moreover, blood lactate levels following glucose loading were not different in patients and controls. These results fail to support the occurrence of a generalized defect in any mitochondrial respiratory function in Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bravi</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>J J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Dagani</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>T L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Gillespie</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Chase</LastName><ForeName>T N</ForeName><Initials>TN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007773">Lactates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>14611-51-9</RegistryNumber><NameOfSubstance UI="D012642">Selegiline</NameOfSubstance></Chemical><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>E0QN3D755O</RegistryNumber><NameOfSubstance UI="D008090">Lisuride</NameOfSubstance></Chemical><Chemical><RegistryNumber>MNX7R8C5VO</RegistryNumber><NameOfSubstance UI="D002230">Carbidopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001786">Blood Glucose</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001792">Blood Platelets</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002230">Carbidopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004734">Energy Metabolism</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007773">Lactates</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019344">Lactic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008090">Lisuride</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010101">Oxygen Consumption</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011954">Receptors, Dopamine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012642">Selegiline</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1620140</ArticleId><ArticleId IdType="doi">10.1002/mds.870070307</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D33 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004D33 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:1620140
|texte= Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:1620140" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |